Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market is estimated to be worth around USD 2

Given the invasive and cost-intensive nature of tissue biopsies, there is a significant unmet need for safer and more patient-friendly cancer diagnostics that are capable of offering highly accurate, and actionable insights related to the disease.
Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market, Forecast to 2030
The financial opportunity within the liquid biopsy and other non-invasive cancer diagnostics market has been analyzed across the following segments:
Type of Tumor Marker
• ctDNA
• cfDNA
• CTCs
• Exosomes
• Others
• Diagnosis / Early Diagnosis
• Patient Monitoring
• Recurrence Monitoring
Target Cancer Indication
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Bladder Cancer
• Melanoma
• Gastric Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others
End Users
• Hospitals
• Research Institutes
• Others
Key Geographical Regions
• North America
• Europe
• Asia-Pacific
• Rest of the World

Leave a Reply

Your email address will not be published. Required fields are marked *